Patents by Inventor Eiji Kawanishi
Eiji Kawanishi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240120709Abstract: The present technology provides a surface emitting element capable of enabling highly accurate detection of an optical characteristic of an emitted light and/or enabling adjustment of the optical characteristic of the emitted light. The surface emitting element of the present technology provides a surface emitting element including a light emitting layer, a characteristic layer that is disposed on an optical path of light generated in the light emitting layer, exhibits an electrical characteristic due to light incidence, and/or has variability in an optical characteristic due to voltage application, and a plurality of electrodes provided on the characteristic layer.Type: ApplicationFiled: January 19, 2022Publication date: April 11, 2024Inventors: EIJI NAKAYAMA, TATSUSHI HAMAGUCHI, KENTARO HAYASHI, RINTARO KODA, HIDEKAZU KAWANISHI
-
Publication number: 20240002343Abstract: The present invention provides a compound for treating or preventing diseases caused by mitochondrial hyperfission. The present invention provides a compound represented by formula (1): wherein R1 and R1? are each independently hydrogen, an optionally substituted lower alkyl, an optionally substituted lower cycloalkyl, and the like; R2 is an optionally substituted lower alkyl, an optionally substituted lower cycloalkyl, and the like; R3 and R4 are each independently hydrogen, halogen, hydroxy, nitro, cyano, an optionally substituted lower alkyl, and the like; R5 and R6 are each independently an optionally substituted lower alkyl; an optionally substituted lower cycloalkyl, and the like; X is nitrogen or oxygen; Y is carbon, nitrogen or oxygen; and a broken line represents the presence or absence of a bond; or a pharmaceutically acceptable salt, a solvate, or a prodrug thereof.Type: ApplicationFiled: November 29, 2021Publication date: January 4, 2024Applicant: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATIONInventors: Eiji KAWANISHI, Akio OJIDA, Motohiro NISHIDA, Yuri KATO
-
Patent number: 10961269Abstract: A method for preparing a compound represented by general formula I: or a salt thereof includes a step of reacting a compound represented by formula II: with a reducing agent to cleave an oxazolidine ring fused to a cycle A?. The reducing agent includes at least one of phosphines, metal hydrides, or transition metal catalysts in the presence of hydrogen gas.Type: GrantFiled: September 20, 2016Date of Patent: March 30, 2021Assignees: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITYInventors: Satoshi Obika, Eiji Kawanishi, Hiroaki Sawamoto, Shuhei Yamakoshi, Yuuki Aral, Shinji Kumagai
-
Publication number: 20180282363Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.Type: ApplicationFiled: June 5, 2018Publication date: October 4, 2018Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Sumihiro NOMURA, Eiji KAWANISHI, Kiichiro UETA
-
Publication number: 20180251488Abstract: The present invention provides a method for producing guanidine crosslinked artificial nucleic acid (abbreviated hereinafter as GuNA), and an intermediate compound for the production thereof. Specifically, the present invention provides a method for producing a compound represented by general formula I: (in the formula, R1, R2, R3, R4, R5, R6, m and ring A are as defined in the specification) or a salt thereof wherein a reducing agent is reacted with a compound represented by general formula II: (in the formula, R1, R2, R3, R4, R5, R6, m, and ring A? are as defined in the specification).Type: ApplicationFiled: September 20, 2016Publication date: September 6, 2018Applicants: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITYInventors: Satoshi OBIKA, Eiji KAWANISHI, Hiroaki SAWAMOTO, Shuhei YAMAKOSHI, Yuuki ARAI, Shinji KUMAGAI
-
Publication number: 20160108078Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.Type: ApplicationFiled: December 28, 2015Publication date: April 21, 2016Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Sumihiro NOMURA, Eiji KAWANISHI, Kiichiro UETA
-
Patent number: 8969376Abstract: The present invention relates to a compound represented by formula [I]: wherein: R1 is hydrogen, halogen, lower alkyl or cyano; Ring A is an optionally substituted heterocyclic group; Ring B is an optionally substituted 3 to 6-membered monocyclic group; and Y is optionally substituted amino, optionally substituted cyclic amino, optionally substituted aliphatic 3 to 6-membered monocyclyloxy, optionally substituted lower alkyl or optionally substituted lower alkyl-O—, or a pharmaceutically acceptable salt thereof, and to their use as PDE10 inhibitor.Type: GrantFiled: February 25, 2011Date of Patent: March 3, 2015Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Eiji Kawanishi, Mitsuya Hongu, Yoshihito Tanaka
-
Publication number: 20140296506Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.Type: ApplicationFiled: June 9, 2014Publication date: October 2, 2014Inventors: Sumihiro NOMURA, Eiji KAWANISHI, Kiichiro UETA
-
Patent number: 8785403Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.Type: GrantFiled: June 12, 2012Date of Patent: July 22, 2014Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Sumihiro Nomura, Eiji Kawanishi, Kiichiro Ueta
-
Publication number: 20130341934Abstract: There is provided a hybrid power generating system for hydraulic power, thermal power (nuclear power) turbines, geothermal, an engine room of a ship, wind power, solar power, a train (high-speed underground electric railway). The system of the present invention for existing hydraulic power, thermal power (nuclear power) turbines, geothermal, an engine room of a ship, wind power, solar power, a train (high-speed underground electric railway), a factory or the like is installed in a space for a power generator in sites of primary, secondary, tertiary substations.Type: ApplicationFiled: August 20, 2010Publication date: December 26, 2013Inventor: Eiji Kawanishi
-
Patent number: 8513202Abstract: A novel crystal form of 1-(?-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum.Type: GrantFiled: May 9, 2011Date of Patent: August 20, 2013Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Sumihiro Nomura, Eiji Kawanishi
-
Publication number: 20120309754Abstract: The present invention relates to a compound represented by formula [I]: wherein: R1 is hydrogen, halogen, lower alkyl or cyano; Ring A is an optionally substituted heterocyclic group; Ring B is an optionally substituted 3 to 6-membered monocyclic group; and Y is optionally substituted amino, optionally substituted cyclic amino, optionally substituted aliphatic 3 to 6-membered monocyclyloxy, optionally substituted lower alkyl or optionally substituted lower alkyl-O—, or a pharmaceutically acceptable salt thereof, and to their use as PDE10 inhibitor.Type: ApplicationFiled: February 25, 2011Publication date: December 6, 2012Inventors: Eiji Kawanishi, Mitsuya Hongu, Yoshihito Tanaka
-
Publication number: 20120258913Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.Type: ApplicationFiled: June 12, 2012Publication date: October 11, 2012Inventors: Sumihiro NOMURA, Eiji KAWANISHI, Kiichiro UETA
-
Patent number: 8222219Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.Type: GrantFiled: July 1, 2011Date of Patent: July 17, 2012Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Sumihiro Nomura, Eiji Kawanishi, Kiichiro Ueta
-
Patent number: 8202984Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.Type: GrantFiled: January 13, 2011Date of Patent: June 19, 2012Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Sumihiro Nomura, Eiji Kawanishi, Kiichiro Ueta
-
Publication number: 20120058941Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.Type: ApplicationFiled: July 1, 2011Publication date: March 8, 2012Inventors: Sumihiro NOMURA, Eiji Kawanishi, Kiichiro Ueta
-
Publication number: 20110212905Abstract: A novel crystal form of 1-(?-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum.Type: ApplicationFiled: May 9, 2011Publication date: September 1, 2011Inventors: Sumihiro Nomura, Eiji Kawanishi
-
Publication number: 20110166135Abstract: The present invention provides aromatic nitrogen-containing 6-membered ring compounds having excellent PDE10 inhibitory activity.Type: ApplicationFiled: September 9, 2009Publication date: July 7, 2011Inventors: Hiroshi Morimoto, Toshiaki Sakamoto, Toshiyuki Himiyama, Eiji Kawanishi, Takehiko Matsumura
-
Publication number: 20110160206Abstract: The present invention provides a tri-substituted pyrimidine compound having an excellent PDE10 inhibitory activity. The present invention relates to a tri-substituted pyrimidine compound represented by the following formula [I0] or a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of said compound for PDE10 inhibitor, and a pharmaceutical composition comprising said compounds as an active ingredient: wherein: either one of X1 and X2 is N, and the other of X1 and X2 is CH; A is *-CH?CH—, *-C(Alk)=CH—, *-CH2—CH2— or *-O—CH2— (* is a bond with R1); Alk is a lower alkyl group; Ring B is an optionally substituted nitrogen-containing aliphatic heterocyclic group; R1 is an optionally substituted quinoxalinyl or an optionally substituted quinolyl; Y0 is mono- or di-substituted amino group, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 3, 2009Publication date: June 30, 2011Inventors: Eiji Kawanishi, Takehiko Matsumura
-
Patent number: 7943788Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); a pharmaceutically acceptable salt thereof, or a prodrug thereof.Type: GrantFiled: January 31, 2005Date of Patent: May 17, 2011Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Sumihiro Nomura, Eiji Kawanishi, Kiichiro Ueta